Dago Advisory.
We help boards and management teams understand where AI changes the structure of their organisations — which functions it transforms, which roles it replaces, and which it creates from scratch.
Dago Advisory is an AI advisory firm based in Gdańsk, Poland. Our work sits at the intersection of strategic advisory and applied AI — we don't just map what AI can do, we help organisations decide what to do about it.
The AI Disclosure Index is our research product. We built it because we kept having the same conversation with clients: 'what is everyone else doing?' The Index answers that question with data, not anecdote — and puts it in the public domain, because the conversation is more useful when more people can participate in it.
Advisory engagements are separate from the Index. If a board or management team wants to understand what their disclosure score means for their strategy — or wants to think through what AI means for their organisation more broadly — we're available for that conversation.
Michał Skwarczyński.
You build the one that holds up in a specific room.
Twenty years in restructuring, finance, M&A and venture architecture. The last six building AI that enters clinical work.
Started with Oxford PPE, moved through M&A at Minova, airline restructurings at Seabury, short-side equity at Chiral and Morphic. Around 2017 classical finance started to feel narrow — I built Human Financial, a startup retirement fund, and later FairVine Super in Australia.
In 2020 I founded Spark Stream as venture architect — assembling companies against an investor brief across climate, fintech, medtech, and algorithmic trading. Five ventures, all still operating.
In 2024 I founded Kontexa — clinical AI for addiction recovery, regulatory class CE I→IIa. That's where the question of AI and role structure became acute: which roles in a therapeutic team does AI support, which does it replace, which does it create? The Index grew out of trying to answer that question systematically.
Career.
Get in touch.
For methodology questions, press enquiries, or advisory conversations — use the contact form or write directly.